RGEN News and Press, Repligen Corporation From 02/20/20

Repligen ( RGEN ) Q4 results : More news on: Repligen Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growth Overall organic revenue growth was 21% for the fourth quarter and 33% for the year 2019 WALTHAM, Mass., Feb. 20, 2020 (GLOBE...

A vast majority of our articles are based on conservative or income-oriented strategies mostly focused on retirees, near-retirees, or folks who are within 10-20 years of their retirement. But at the same time, we like investing a limited or small portion of our portfolio in "high-growth stra...

Earnings season is here. That means most public companies have reported or will soon report operating results for the quarter ended Dec. 31. For many, the next report will include full-year 2019 operating results and full-year 2020 guidance. The stakes are higher for some than for others. For i...

WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday, February 20, 2020. The Company will issue a press release before the market opens and will h...

It requires a long-term mindset, but buy-and-hold investing is the best way to build wealth. It reduces costly transaction fees, allows the greatest tax benefits, and reduces the temptation of mixing emotions with money. Even better, the process of buying great businesses at great prices and hol...

Seven of the top 10 best-selling drugs in the world are antibodies, biosimilars are starting to disrupt the pharmaceutical industry, and Big Pharma is investing billions in gene therapy. On top of that, roughly half of the drugs in biopharma pipelines today are biologics (antibodies, cell ther...

This list is a snapshot of the best healthcare stocks for an entire decade, from 2010 to 2020. As such, some magnificent stocks are excluded, simply because of the measurement period. For instance,  Axsome Therapeutics had an amazing 3,578% return in 2019. And yet Axsome's fantastic 2019 r...

WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38 th annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Fr...

Agilent (NYSE: A ) initiated with Hold rating and $85 (11% upside) price target at Stifel. More news on: Agilent Technologies, Inc., Avantor, Inc., Bio-Techne Corporation, Healthcare stocks news, Stocks on the move, , Read more ...